Literature DB >> 12111700

Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells.

Rana Dutta1, Donald A Sens, Seema Somji, Mary Ann Sens, Scott H Garrett.   

Abstract

BACKGROUND: The third isoform of metallothionein (MT-3) is overexpressed in prostate cancers and PIN lesions. The expression of MT-3 is highly variable but appears to correlate to Gleason score. The goal of the present study was to determine the effect of MT-3 overexpression on the growth of the PC-3 prostate cancer cell line.
METHODS: PC-3 cells were stably transfected with either the MT-3 or MT-1E gene. Cell growth was determined by counting DAPI-stained nuclei, drug resistance by the colony formation assay, MT mRNA expression by reverse transcriptase-polymerase chain reaction, and MT protein by immunoblot.
RESULTS: PC-3 cells that overexpress the MT-3 gene are growth inhibited compared with either untransfected cells, cells with blank vector, or cells with similar overexpression of the MT-1E gene. Furthermore, increased chemotherapeutic drug resistance occurred in PC-3 clones derived from MT-3- and MT-1E-transfected cells.
CONCLUSION: The overexpression of MT-3 can influence the growth and chemotherapeutic drug resistance of the PC-3 prostate cancer cell line. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111700     DOI: 10.1002/pros.10097

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  14 in total

1.  Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control.

Authors:  Seema Somji; Scott H Garrett; Xu Dong Zhou; Yun Zheng; Donald A Sens; Mary Ann Sens
Journal:  Toxicol Environ Chem       Date:  2010-10       Impact factor: 1.437

Review 2.  Chemistry and biology of mammalian metallothioneins.

Authors:  Milan Vašák; Gabriele Meloni
Journal:  J Biol Inorg Chem       Date:  2011-06-07       Impact factor: 3.358

3.  Identification of mouse brain proteins associated with isoform 3 of metallothionein.

Authors:  David W Lahti; John D Hoekman; Abigail M Tokheim; Bruce L Martin; Ian M Armitage
Journal:  Protein Sci       Date:  2005-03-31       Impact factor: 6.725

4.  Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

Authors:  S L El Sharkawy; N F Abbas; M A Badawi; M A El Shaer
Journal:  J Clin Pathol       Date:  2006-03-30       Impact factor: 3.411

5.  Reaction of human metallothionein-3 with cisplatin and transplatin.

Authors:  Andrei V Karotki; Milan Vasák
Journal:  J Biol Inorg Chem       Date:  2009-06-18       Impact factor: 3.358

6.  Metallothionein-3 (MT-3) in the human adrenal cortex and its disorders.

Authors:  Saulo J A Felizola; Yasuhiro Nakamura; Yuki Arata; Kazue Ise; Fumitoshi Satoh; William E Rainey; Sanae Midorikawa; Shinichi Suzuki; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

7.  Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells.

Authors:  Takashi Otsuka; Aki Hamada; Kazuhiro Iguchi; Shigeyuki Usui; Kazuyuki Hirano
Journal:  Biomed Rep       Date:  2013-05-17

8.  Role of metallothioneins in benign and malignant thyroid lesions.

Authors:  Bartosz Pula; Pawel Domoslawski; Marzena Podhorska-Okolow; Piotr Dziegiel
Journal:  Thyroid Res       Date:  2012-12-28

9.  Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation.

Authors:  Eric Smith; Paul A Drew; Zi-Qing Tian; Neville J De Young; Jun-Feng Liu; George C Mayne; Andrew R Ruszkiewicz; David I Watson; Glyn G Jamieson
Journal:  Mol Cancer       Date:  2005-12-13       Impact factor: 27.401

10.  Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues.

Authors:  Hua Wei; Mohamed Mokhtar Desouki; Shufei Lin; Dakai Xiao; Renty B Franklin; Pei Feng
Journal:  Mol Cancer       Date:  2008-01-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.